Latest news with #RVTY
Yahoo
24-05-2025
- Business
- Yahoo
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity, Inc. RVTY announced the launch of its new IDS i20 analytical random-access platform from EUROIMMUN. Per management, it is expected to enable full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 instrument is equipped with the ability to process up to 140 tests per hour (assay dependent) and is the latest addition to RVTY's well-established IDS i-device series. The latest product availability is expected to boost Revvity's Immunodiagnostics product line under the broader Diagnostics segment. Following the announcement, shares of the company lost nearly 2.9% till yesterday's closing. Historically, the company has gained a top-line boost from its various product launches. Although the latest product availability is likely to be beneficial for RVTY's top-line growth going forward, the stock declined overall. Revvity currently has a market capitalization of $10.67 billion. It has an earnings yield of 5.3%, favorable than the industry's 4.1%. In the last reported quarter, RVTY delivered an earnings surprise of 5.2%. Per Revvity, the IDS i20 platform is a CE-marked and FDA-listed device that will likely allow laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The IDS i20 platform is expected to offer fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease and therapeutic drug monitoring. Management believes that the IDS i20 instrument will be able to support Revvity's customers in transitioning from manual and semi-automated processing to a fully automated solution for enhanced immunodiagnostics workflows. Per a report by Grand View Research, the global ChLIA market was estimated at $11.71 billion in 2023 and is anticipated to witness a CAGR of 4.6% between 2024 and 2030. Factors like the growing emphasis on early disease detection and increased efforts by pharmaceutical companies in drug discovery and development are likely to drive the market. Given the market potential, the latest product launch is expected to be a significant milestone for Revvity and boost its business. Last month, Revvity announced its first-quarter 2025 results, wherein its Diagnostics segment recorded a robust year-over-year revenue growth both on a reported and organic basis. In March, Revvity announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. In January, Revvity received the FDA's 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay test for free testosterone. Shares of the company have lost 20.2% in the past year compared with the industry's 20.9% decline. The S&P 500 has gained 10% in the same time frame. Image Source: Zacks Investment Research Currently, RVTY carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR. Hims & Hers, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 36.5%. HIMS' earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 19.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Hims & Hers' shares have surged 217.1% compared with the industry's 13.5% growth in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 32.5% against the industry's 20.9% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have lost 3.7% compared with the industry's 14.7% plunge in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
01-05-2025
- Business
- Yahoo
1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could offer consistent gains and two stuck in limbo. Rolling One-Year Beta: 0.19 Originally founded as a Wisconsin paper mill in 1872, Kimberly-Clark (NYSE:KMB) is now a household products powerhouse known for personal care and tissue products. Why Is KMB Not Exciting? Flat unit sales over the past two years show it's struggled to move its products and had to rely on price increases Demand will likely be weak over the next 12 months as Wall Street expects flat revenue Free cash flow margin has stayed in place over the last year Kimberly-Clark is trading at $130.11 per share, or 17.3x forward price-to-earnings. Read our free research report to see why you should think twice about including KMB in your portfolio, it's free. Rolling One-Year Beta: 0.69 Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Do We Think RVTY Will Underperform? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $92.67 per share, Revvity trades at 18x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than RVTY. Rolling One-Year Beta: 0.82 Founded during the dot-com era in 1999 and specializing in high-intent consumer traffic, QuinStreet (NASDAQ:QNST) operates digital performance marketplaces that connect clients in financial and home services with consumers actively searching for their products. Why Is QNST a Good Business? Annual revenue growth of 27.1% over the last two years was superb and indicates its market share increased during this cycle Revenue outlook for the upcoming 12 months is outstanding and shows it's on track to gain market share Earnings per share have massively outperformed its peers over the last two years, increasing by 99.4% annually QuinStreet's stock price of $17.52 implies a valuation ratio of 17.8x forward price-to-earnings. Is now the right time to buy? See for yourself in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
